Lymphoma, Large-cell - 75 Studies Found
Completed |
: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma :
: Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion |
Completed |
: Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma : Anaplastic Large-Cell Lymphoma : 2004-03-12 : Drug: SGN-30 (anti-CD30 mAb) |
Terminated |
: SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma : Anaplastic Large Cell Lymphoma : 2006-08-16 :
|
Withdrawn |
: A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib : Systemic Anaplastic Large-Cell Lymphoma : 2015-06-30 : Drug: crizotinib crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vinc |
Active, not recruiting |
: Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma : Anaplastic Large-cell Lymphoma : 2013-07-01 : Drug: brentuximab vedotin Brentuximab vedotin will be administered as a single intravenous (IV) infusion |
Recruiting |
: Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) :
: 2016-10-18 : Drug: Brentuximab Vedotin Brentuximab vedotin IV infusion. |
Terminated |
: Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma :
|
Not yet recruiting |
: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma :
|
Recruiting |
: Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma" : Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma : 2014-04-17 : Drug: Brentuximab vedotin (recombinant) Brentuximab vedotin (recombinant) for IV infusion |
Completed |
: A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma :
: 2013-09-23 :
|